AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05539625 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MitoQ
Description: MitoQ in inflammation: In the experimental setting, MitoQ has been extensively studied with clear mode of action on inflammatory mechanisms relevant to IBD:~MitoQ can limit the damage to mitochondria caused by mitochondrial ROS and thereby reducing the leak and oxidisation of mtDNA that are critical to its pro-inflammatory actions within the cell.~MitoQ reduces the inflammatory potential of mitochondrial DNA which have escaped or released from dying inflammatory cells.~MitoQ can influence how the immune cells generate their energy, diverting it away from a more inflammatory type of metabolism (glycolysis) MitoQ can induce autophagy, a cellular recycling mechanism that removes damaged mitochondria. Defective autophagy is heavily implicated in the pathogenesis of IBD.~Hence collectively, MitoQ acts upstream of several pro-inflammatory mechanisms with the net effect to promote resolution of inflammation and mucosal healing.
Study NCT05539625 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05282550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trazodone
Description: 50mg of trazodone administered for 4 weeks.
Study NCT05282550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Description: 50mg of trazodone administered for 4 weeks.
Study NCT05282550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered for 4 weeks.
Study NCT05282550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo administered for 4 weeks.
Study NCT06025916 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic acid
Description: 20 ml of oral solution TA (100mg/ml)
Study NCT06025916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: 20 ml of oral solution TA (100mg/ml)
Study NCT05176314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Administered Orally.
Study NCT05176314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Administered Orally.
Study NCT05543265 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Default appointment scheduling
Description: Default primary care appointment scheduling
Study NCT05543265 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted messaging
Description: Patient-specific messages about the importance of postpartum care transition
Study NCT05543265 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudge Reminders
Description: Primary care appointment reminders
Study NCT05318131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep and Lifestyle Advice Website
Description: Participants will be asked to view a website at least once a week for 3 months (remotely). The website includes information about exercise, nutrition and sleep. Participants will also have a check-in call with a health coach at 6 weeks, and will be sent email newsletters at approximately 1 and 2 months with additional information about sleep, nutrition, and exercise.
Study NCT05318131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surveys and Sleep Monitors
Description: At baseline and at 3 months, participants will be asked to complete online surveys and to wear an ActiGraph sleep monitor for one week. ActiGraph sleep monitors are wristbands that measure continuous sleep/wake activity information. The recorded ActiGraph data is deidentified and no individual personally identifiable information is collected. A unique serial number identifies each wrist monitor. At the end of the study, participants will also have a telephone exit interview with the study team to provide feedback on their progress during the study and about the website.
Study NCT05568225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etavopivat
Description: 400 mg once daily
Study NCT04530981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ripretinib
Description: Oral KIT/PDGFRA kinase inhibitor
Study NCT04530981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: Oral antihyperglycemic agent
Study NCT04736888 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: extended-reality CPR training
Description: extended-reality technologies based CPR training module
Study NCT04736888 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: conventional CPR training
Description: conventional CPR training with video
Study NCT04854135 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM4Home
Description: FreeStyle Libre 2 Continuous Glucose Monitoring System manufactured by Abbott
Study NCT05590481 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TIBIAL TRANSCUTANEOUS ELECTROSTIMULATION
Description: The electrodes will be surface (silicone rubber and carbonate), brand Quark®, with dimensions of 5 cm by 3 cm, coupled with conductive gel and fixed to the volunteer's skin with micropore tape. For the placement of the electrodes, the volunteer will be positioned in the horizontal supine position on the stretcher, with the knee in semiflexion and the head supported on a pillow. The electrodes will be positioned one immediately posterior to the medial malleolus of the ankle and the other approximately 10 cm above it, both fixed with micropore tape, on both legs of the patient. To ensure that the electrodes stimulate the tibial nerve, a transcutaneous electrical nerve stimulation (TENS) current with a frequency of 1 Hz will first be applied, with a gradual increase in intensity, to verify a rhythmic movement of flexion of the hallux. The following parameters will be used for TTNS: frequency 10Hz (Hertz), pulse duration 200 μs (microseconds), for 30 minutes.
Study NCT05590481 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral therapy protocol
Description: submitted to a behavioral therapy protocol, which involves bladder training, pelvic floor muscle training and modification of liquid intake. The orientation will be based on the initial evaluation of the patient, in which the responsible researcher will give verbal orientations and deliver booklets on the pathology, behavioral therapy and sleep hygiene.
Study NCT05590481 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: behavioral therapy protocol
Description: submitted to a behavioral therapy protocol, which involves bladder training, pelvic floor muscle training and modification of liquid intake. The orientation will be based on the initial evaluation of the patient, in which the responsible researcher will give verbal orientations and deliver booklets on the pathology, behavioral therapy and sleep hygiene.
Study NCT05323695 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Depression Screening Intervention
Description: All participants will be screened for depression using PHQ-2 and PHQ-9. Those screened positive for PHQ-2 but decline further screening with PHQ-9 will be assisted for further assessment or care. Those with mild to severe symptoms (score of 7 or higher on PHQ-9) will be assisted for further assessment or care with a psychiatrist.
Study NCT06360302 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Exercise test
Description: Metabolic effort test on cycloergometer with gas measurement. Gas exchanges (V'O2 and V'CO2) will be measured cycle-by-cycle using a gas analyzer connected to a flow meter Measurements will be taken every 6 minutes, at rest and during exercise on a cycloergometer, in five 6-minute increments, corresponding to intensities of 0% (rest), 20%, 30%, 40%, 50 and 60% of the subject's estimated maximum power, for a total duration of around 45 minutes.
Study NCT06360302 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Exercise test
Description: Metabolic effort test on cycloergometer with gas measurement. Gas exchanges (V'O2 and V'CO2) will be measured cycle-by-cycle using a gas analyzer connected to a flow meter Measurements will be taken every 6 minutes, at rest and during exercise on a cycloergometer, in five 6-minute increments, corresponding to intensities of 0% (rest), 20%, 30%, 40%, 50 and 60% of the subject's estimated maximum power, for a total duration of around 45 minutes.
Study NCT06360302 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: A catheter will be placed in a forearm vein to take blood samples at rest and at the end of the 5-stage stress test.~Sampling times synchronized with stress test measurements
Study NCT06360302 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Description: A catheter will be placed in a forearm vein to take blood samples at rest and at the end of the 5-stage stress test.~Sampling times synchronized with stress test measurements
Study NCT06360302 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Impedancemetry
Description: measurement of anthropometric data (weight, height, waist circumference). impedancemetry will enable body composition to be analyzed by placing surface electrodes on the body. The participant will lie on an examination table and must remain at rest for 5 minutes.
Study NCT06360302 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Impedancemetry
Description: measurement of anthropometric data (weight, height, waist circumference). impedancemetry will enable body composition to be analyzed by placing surface electrodes on the body. The participant will lie on an examination table and must remain at rest for 5 minutes.
Study NCT05137041 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ITP FIRTECH
Description: Infrared Therapy Patch
Study NCT06383858 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Screening method
Description: All pregnant women in the group were screened for pre-eclampsia risk according to the clinical risk factors listed in NICE Guidelines (2019).
Study NCT06383858 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Screening method
Description: In the first trimester, pregnant women with routine MAP and PLGF (with UtA-PI detection conditions plus UtA-PI) were tested, and the risk of preeclampsia was evaluated based on Bayes rule combined with maternal factors. In the second and third trimester of pregnancy, routine determination of PLGF or sFlt-1/PLGF was used to evaluate the risk of preeclampsia.
Study NCT06187896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remimazolam
Description: in this group,patients are treated with remimazolam and remifentanil for reduced sedation.
Study NCT06187896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: in this group,patients are treated with propofol and remifentanil for reduced sedation.
Study NCT05533385 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allergenic extract
Description: In each subject a drop of each of the 3 concentrations of both allergenic extracts will be applied in addition to the positive control (histamine) and the negative control. The application will be made in duplicate on the anterior face of the subject's arm. The distance between each application should be approximately 4 cm.
Study NCT05595486 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baby2Home Mobile Application
Description: Baby2Home is a digital health intervention designed to bridge the resultant gaps in obstetrics and pediatrics healthcare services for new families over the first year of life.
Study NCT04647227 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: coagulation factor VIIa [recombinant]-jncw
Description: a transgenically produced, activated, recombinant, human factor VII (rhFVIIa) protein with the brand name of SEVENFACT®. This protein is a clotting factor in the coagulation cascade that is produced in and purified from the milk of transgenic rabbits. SEVENFACT is approved for the treatment and control of bleeding episodes occurring in adults and adolescents (12 years of age and older) with hemophilia A or B with inhibitors.
Study NCT05164120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belnacasan
Description: Oral administration
Study NCT05164120 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet containing 0mg of API
Study NCT05398757 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mini mental state exame (MMSE)
Description: Before the operation, and on the 1st, 3rd and 5th day after the operation, the Mini mental state exam (MMSE) score will be measured
Study NCT05398757 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mini mental state exame (MMSE)
Description: Before the operation, and on the 1st, 3rd and 5th day after the operation, the Mini mental state exam (MMSE) score will be measured
Study NCT05398757 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digit Symbol Substitution Test (DSST)
Description: Before the operation, and on the 1st, 3rd and 5th day after the operation, the Digit Symbol Substitution Test (DSST) score will be measured
Study NCT05398757 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Digit Symbol Substitution Test (DSST)
Description: Before the operation, and on the 1st, 3rd and 5th day after the operation, the Digit Symbol Substitution Test (DSST) score will be measured
Study NCT05398757 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Numeric rating Scale (NRS)
Description: 4h, 8h, 12h and 24h after surgery, pain in all patients will be assessed by the NRS scale.
Study NCT05398757 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Numeric rating Scale (NRS)
Description: 4h, 8h, 12h and 24h after surgery, pain in all patients will be assessed by the NRS scale.
Study NCT05398757 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative inflammation
Description: All patients included in the study will have their blood taken for laboratory analysis of red blood cells, leukocytes, CRP, PCT, ChE and IL-6. Analyzes will be performed before the procedure, on the 1st, 3rd and 5th postoperative day.
Study NCT05398757 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Postoperative inflammation
Description: All patients included in the study will have their blood taken for laboratory analysis of red blood cells, leukocytes, CRP, PCT, ChE and IL-6. Analyzes will be performed before the procedure, on the 1st, 3rd and 5th postoperative day.
Study NCT05398757 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam
Description: For sedation during surgery, patients in midazolam group will receive i.v. midazolam in dose 0.05 - 0.07 mg/kg after spinal anesthesia.
Study NCT05398757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: For sedation during surgery, patients in propofol group will receive i.v. propofol in dose 25-27 mcg/kg/min.
Study NCT05398757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidin
Description: For sedation during surgery, patients in dexmedetomidin gropu will receive i.v. dexmedetomidin in dose 0.5 mcg/kg/h
Study NCT05762679 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Imaging
Description: Phase 1 is an imaging biomarker study.
Study NCT05583773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ShengXian-QuYu Decoction
Description: Specification: 30ml/bag, given twice daily, per oral use.
Study NCT05583773 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching ShengXian-QuYu Decoction, 30ml/bag, given twice daily, per oral use.
Study NCT05983458 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transaortic valve replacement
Description: TAVI procedure will be performed under conscious sedation. Foley urinary catheters and jugular lines will be avoided.~For femoral access, closure devices will be Prostar or ProGlide, which are similar and carry low rates of major vascular complications . Single femoral access and a radial access as the secondary arterial access will be used to reduce the rate of vascular complications.~All procedures will be performed with cerebral protection using the Sentinel device. During valve implantation, commissural alignment will be checked for all patients. As a practical rule, commissural alignment will be checked in co-planar view and in cusp-overlap view.
Study NCT06487572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Intravenous (IV) Infusion
Study NCT06487572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous (SC) Injection
Study NCT06205992 — intervention group
Intervention type: DEVICE
Intervention: 3D-MRE
Description: All imaging studies were performed by using a 3.0-T MRI system (Signa HDx, GE Healthcare) with an eight-channel phasedarray body coil.
Study NCT06205992 — intervention group
Intervention type: DEVICE
Intervention: HVPG
Description: HVPG measurements are performed by well-trained interventional radiologists in accordance with standard operating procedures
Study NCT06205992 — intervention group
Intervention type: DEVICE
Intervention: 2D-MRE
Description: All imaging studies were performed by using a 3.0-T MRI system (Signa HDx, GE Healthcare) with an eight-channel phasedarray body coil.
Study NCT05381948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eyp-1901
Description: Intravitreal Injection
Study NCT05381948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept 2Mg/0.05Ml Inj,Oph
Description: Intravitreal Injection
Study NCT06268236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Electro-acupuncture at Shuigou and Yintang.
Study NCT06268236 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham electroacupuncture
Description: Sham-EA at sham-Shuigou and sham-Yintang.
Study NCT06581471 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Tricuspid Valve Replacement
Description: Replacement of the tricuspid valve through a transcatheter approach
Study NCT06581705 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Video Laryngoscope
Description: Evaluation of the success rates (SR) of anesthetists aged ≥45 years for intubating neonates and infants using the C-MAC videolaryngoscope (VL) in comparison to the use of the standard laryngoscope (SL).
Study NCT04781478 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Application of Biorepair Gel
Description: Professional application of Biorepair Gel after Scaling and Root Planing and Air-Perio polishing (glycine powders).
Study NCT04781478 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Irrigation of Chlorhexidine 1.00% gel
Description: Irrigation of periodontal pockets with Chlorhexidine 1.00% gel afterScaling and Root Planing and Air-Perio polishing (glycine powders).
Study NCT05172128 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lyophilized blueberry supplement
Description: lyophilized blueberry supplement bid
Study NCT05792358 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: wet cupping therapy
Description: wet cupping therapy will be applied to participants in this arm for three sessions once a month
Study NCT06240234 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Capnodynamic method
Description: All patients will be ventilated using the novel capnodynamic method, incorporated in a modified Maquet servo I ventilator. For this reason, all patients will be anesthetized using total intravenous anesthesia.
Study NCT06540053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Static Hamstring Stretch Exercise
Description: In the first session, participants will be instructed on the principles of spinal protection. Following this, members of the experimental group will engage in active hamstring exercises within the office environment. These exercises will be conducted for 10 minutes, consisting of 10 repetitions of 30-40 seconds of stretching followed by 30 seconds of rest, five days a week for six weeks. Participants in the experimental group will be remotely supervised during the stretching exercises.
Study NCT06540053 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Waiting List
Description: Participants will receive workplace training on spine protection principles and subsequently be placed on a waiting list. Throughout this process, individuals in the designated group will receive text messages on Mondays, Wednesdays, and Fridays over the course of six weeks. These messages will contain information aimed at assisting them in maintaining correct posture throughout the workday.
Study NCT04908579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine(intraperitoneally) and ketamine (intraperitoneally)
Description: 1. 40 ml volume of bupivacaine 0.25% + ketamine 0.5 mg/kg distributed as 30 ml intraperitoneally and 10 ml as port site infiltration~2. 10 ml normal saline 0.9% will be given intravenous.
Study NCT04908579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine(intraperitoneally) and ketamine (intravenously)
Description: 1. 40 ml volume of bupivacaine 0.25% only distributed as 30 ml intraperitoneally and 10 ml as port site infiltration~2. 10 ml volume of ketamine 0.5 mg/kg intravenously will be given after delivering the gastric sleeve and before start closure of port sites.
Study NCT04908579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine(intraperitoneally)
Description: 1. 40 ml volume of bupivacaine 0.25% only distributed as 30 ml intraperitoneally and 10 ml as port site infiltration~2. 10 ml normal saline 0.9% will be given intravenous.